Galera Therapeutics, Inc. (GRTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company’s lead ...

MALVERN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary ...

A downtrend has been apparent in Galera Therapeutics, Inc. (GRTX) lately. While the stock has lost 75% over the past two weeks, it could witness a trend reversal as a hammer chart pattern was formed ...

Galera Therapeutics Inc (NASDAQ:GRTX) received official meeting minutes from the Type A meeting with the FDA held last month. The FDA reiterated the need for an additional Phase 3 trial of avasopasem ...

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F ...

Ballard Spahr and Lamb McErlane PC filed a breach-of-contract lawsuit on May 30 in Pennsylvania Court of Common Pleas for Chester County on behalf of drug developer Galera Therapeutics. The suit ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. It is also involved in ...